ICT-140
Ovarian Cancer
Phase 1Seeking Partner
Key Facts
About Precision Life Sciences Group
Precision Lifesciences Group is a private, pre-revenue biotech firm founded in 2016, specializing in novel cell therapies for oncology. Its core technology is the Stem-to-T-Cell platform, an early-stage approach designed to engineer a patient's own stem cells to produce a continuous, controlled supply of tumor-specific killer T cells, potentially offering advantages in safety and durability over existing therapies like CAR-T. The company also holds three clinical-stage dendritic cell vaccine assets (ICT-107, ICT-121, ICT-140) for which it is seeking development partners. With operations in Boston and Nashville, the company is positioned in the competitive but high-potential field of cancer immunotherapy.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |